HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target.
Trinseo Sees Q1 2024 Net Loss From Continuing Operations Of $77M-$67M; Adjusted EBITDA Of $40M-$50M
2024 OutlookFirst quarter 2024 net loss from continuing operations of $77 million to $67 millionFirst quarter 2024 Adjusted EBITDA of $40 million to $50 millionCommenting on the outlook for 2024, Bozich said, "We are